Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors - Naing, Aung; Algazi, Alain P.; Falchook, Gerald S.; Creelan, Benjamin C.; Powderly, John; Rosen, Seth; Barve, Minal; Mettu, Niharika B.; Triozzi, Pierre L.; Hamm, John; Zhou, Gongfu; Walker, Chris; et al. (Cancer, 2023)
Keywords: Adult; Antibodies, Monoclonal - adverse effects; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Apoptosis; Appetite loss; Cell death; Diarrhea; Dioxygenase; durvalumab; epacadostat; Humans; Immune checkpoint inhibitors; Immunotherapy; Inhibitors; kynurenine; Metastases; Monoclonal antibodies; neoplasms; Neoplasms - pathology; Neoplasms, Second Primary - etiology; Oncology; Original; ORIGINAL ARTICLES; Oximes; Patients; PD-1 protein; PD-L1 protein; PD‐1; Pharmacodynamics; Pruritus; Solid tumors; Sulfonamides; Targeted cancer therapy; Tumors; durvalumab; epacadostat; kynurenine; neoplasms; PD-1